PGNY News and Press, Progyny Inc. From 11/20/25

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc . (Nasdaq: PGNY), a global leader in family building solutions, today announced new men’s health research exploring experiences and views on fertility. The findings shed light on how men in the U.S. view their role in the fer...

2025-11-19 08:45:00 ET Progyny ( PGNY ) is the leading go-to provider of fertility benefits to company employees in the US. The firm has enjoyed a series of positive news releases of late, sending the stock price up from $18.01 at the close of Nov 6 to above $27 on Nov 17—a g...

2025-11-17 10:48:59 ET More on Progyny Progyny, Inc. 2025 Q3 - Results - Earnings Call Presentation Progyny, Inc. (PGNY) Q3 2025 Earnings Call Transcript Progyny's Strong Fundamentals And Global Growth: Why I Choose To Buy Progyny upgraded at KeyBanc on catal...

2025-11-12 14:44:35 ET More on Progyny Progyny, Inc. 2025 Q3 - Results - Earnings Call Presentation Progyny, Inc. (PGNY) Q3 2025 Earnings Call Transcript Progyny's Strong Fundamentals And Global Growth: Why I Choose To Buy Progyny signals $200M share repurcha...

2025-11-11 17:07:19 ET from KeyBanc issued a price target of $30.00 for PGNY on 2025-11-11 21:42:57. The adjusted price target was set to $30.00. At the time of the announcement, PGNY was trading at $23.81. The overall price target consensus is at $27.50 with high price ...

2025-11-07 13:02:28 ET Shares of leading fertility and women's health benefits manager Progyny (NASDAQ: PGNY) are up 18% as of 11 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence . Progyny reported third-quarter earnings Thursday afternoon ...

2025-11-06 19:26:57 ET More on Progyny Progyny, Inc. (PGNY) Q3 2025 Earnings Call Transcript Progyny's Strong Fundamentals And Global Growth: Why I Choose To Buy Progyny Non-GAAP EPS of $0.45 beats by $0.06, revenue of $313.3M beats by $14.07M Progyny Q3 2025...

2025-11-06 19:26:07 ET Progyny, Inc. (PGNY) Q3 2025 Earnings Call November 6, 2025 4:45 PM EST Company Participants James Hart - Vice President of Investor Relations Peter Anevski - CEO & Director Mark Livingston - Chief Financial Officer Michael Sturmer ...

2025-11-06 16:02:18 ET More on Progyny Progyny's Strong Fundamentals And Global Growth: Why I Choose To Buy Progyny Q3 2025 Earnings Preview Progyny seesaws amid confusion over impact from Trump’s IVF initiative Seeking Alpha’s Quant Rating on P...

Reports Revenue of $313.3 Million, Reflecting 9.3% Growth Raises Full Year Guidance to Reflect Continued Strength in Member Engagement Selling Season Yields Over 80 New Clients, 900,000 New Lives, and Near 100% Retention of Existing Base Record $156.0 Million in Operating Cash Flow Generate...